BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1718090)

  • 1. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro.
    Cordell J; Moore JP; Dean CJ; Klasse PJ; Weiss RA; McKeating JA
    Virology; 1991 Nov; 185(1):72-9. PubMed ID: 1718090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Ho DD; Fung MS; Cao YZ; Li XL; Sun C; Chang TW; Sun NC
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8949-52. PubMed ID: 1717992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
    J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA; Cordell J; Dean CJ; Balfe P
    Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.
    McKeating JA; Thali M; Furman C; Karwowska S; Gorny MK; Cordell J; Zolla-Pazner S; Sodroski J; Weiss RA
    Virology; 1992 Sep; 190(1):134-42. PubMed ID: 1382339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    Ho DD; McKeating JA; Li XL; Moudgil T; Daar ES; Sun NC; Robinson JE
    J Virol; 1991 Jan; 65(1):489-93. PubMed ID: 1702163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120.
    DeVico AL; Rahman R; Welch J; Crowley R; Lusso P; Sarngadharan MG; Pal R
    Virology; 1995 Aug; 211(2):583-8. PubMed ID: 7544051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
    Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA
    J Virol; 1995 Jan; 69(1):222-30. PubMed ID: 7527084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
    J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.
    Dowbenko D; Nakamura G; Fennie C; Shimasaki C; Riddle L; Harris R; Gregory T; Lasky L
    J Virol; 1988 Dec; 62(12):4703-11. PubMed ID: 2460639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.
    Dennison SM; Anasti KM; Jaeger FH; Stewart SM; Pollara J; Liu P; Kunz EL; Zhang R; Vandergrift N; Permar S; Ferrari G; Tomaras GD; Bonsignori M; Michael NL; Kim JH; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Liao HX; Haynes BF; Alam SM
    J Virol; 2014 Aug; 88(16):9406-17. PubMed ID: 24920809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
    AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
    Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
    J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins.
    He Y; D'Agostino P; Pinter A
    Vaccine; 2003 Oct; 21(27-30):4421-9. PubMed ID: 14505925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site.
    McKeating JA; Moore JP; Ferguson M; Marsden HS; Graham S; Almond JW; Evans DJ; Weiss RA
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):451-9. PubMed ID: 1376134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.